Debiopharm Group™ (Debiopharm) and Vifor Pharma have announced the signing of an exclusive agreement covering the distribution and commercialization in Switzerland of the 1-, 3- and 6-month formulations of Pamorelin® LA and of the 3-month formulation of Salvacyl®.
The agreement came into effect on 9 May 2012. Pamorelin® LA, which contains the active substance triptorelin in the form of pamoate salt, is indicated in the treatment of advanced hormone-dependent prostate cancer, endometriosis and female infertility.
Salvacyl® is indicated in the treatment of severe sexual deviation in men. The 1- and 3-month formulations of Pamorelin® LA are available immediately, while the introduction of the 6-month formulation of Pamorelin® LA and Salvacyl® will be communicated by Vifor Pharma at a later date.
Developed by Debiopharm, the products Pamorelin® LA and Salvacyl® are manufactured by Debio R.P. in Martigny, Debiopharm's site for applied research, controlled release formulation development and production.
"We are very happy that Vifor Pharma and Debiopharm can offer a drug with the added value of Pamorelin® LA to prostate cancer patients and that Pamorelin® LA will be marketed in Switzerland by a well-established Swiss company such as Vifor Pharma," emphasized Rolland-Yves Mauvernay, founder and President of Debiopharm.
“With Debiopharm we have found a renowned Swiss partner. This move will enable us to provide patients and doctors with an innovative product in the areas of oncology and gynaecology," added Josef Troxler, General Manager of the Swiss affiliate of Vifor Pharma.